This comparable HR of the BRAF V600E mutation for recurrences remained non-significant (pooled HR 1.16, 95% CI 0.78–1.71) after adjustment for potential confounders, including age, sex, and tumor size (Figure 3). This evidence concerns the gene BRAF and neoplasm.